ACADIA Pharmaceuticals Inc
ACAD22.200USD
-0.370-1.64%
Cierre 11/10, 16:00（ET）Cotizaciones retrasadas 15 min
3.76BCap. mercado
14.38P/E TTM
Más Datos de ACADIA Pharmaceuticals Inc Compañía
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Información de ACADIA Pharmaceuticals Inc
Símbolo de cotizaciónACAD
Nombre de la empresaACADIA Pharmaceuticals Inc
Fecha de salida a bolsaMay 27, 2004
Director ejecutivoMs. Catherine Owen Adams
Número de empleados653
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 27
Dirección12830 El Camino Real
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92130
Teléfono18585582871
Sitio Webhttps://acadia.com/
Símbolo de cotizaciónACAD
Fecha de salida a bolsaMay 27, 2004
Director ejecutivoMs. Catherine Owen Adams
Ejecutivos de ACADIA Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Director
Independent Director
102.88K
--
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Independent Director
Independent Director
24.80K
+60.90%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.10K
-48.90%
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Executive Vice President and Head of Research and Development
Executive Vice President and Head of Research and Development
--
--
Mr. Mark C. Schneyer
Mr. Mark C. Schneyer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Edmund P. Harrigan
Dr. Edmund P. Harrigan
Independent Director
Independent Director
--
--
Mr. Thomas Andrew (Tom) Garner
Mr. Thomas Andrew (Tom) Garner
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Ms. Catherine Owen Adams
Ms. Catherine Owen Adams
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Director
Independent Director
102.88K
--
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Independent Director
Independent Director
24.80K
+60.90%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.10K
-48.90%
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Executive Vice President and Head of Research and Development
Executive Vice President and Head of Research and Development
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q2
FY2023Q1
Por negocioUSD
Nombre
Ganancia
Proporción
NUPLAZID
168.48M
63.68%
DAYBUE
96.09M
36.32%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
NUPLAZID
168.48M
63.68%
DAYBUE
96.09M
36.32%
Estadísticas de accionistas
Actualizado: mié., 8 de oct
Actualizado: mié., 8 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Baker Bros. Advisors LP
25.36%
BlackRock Institutional Trust Company, N.A.
10.77%
The Vanguard Group, Inc.
8.96%
RTW Investments L.P.
5.32%
State Street Investment Management (US)
3.65%
Otro
45.95%
Accionistas
Accionistas
Proporción
Baker Bros. Advisors LP
25.36%
BlackRock Institutional Trust Company, N.A.
10.77%
The Vanguard Group, Inc.
8.96%
RTW Investments L.P.
5.32%
State Street Investment Management (US)
3.65%
Otro
45.95%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
36.76%
Investment Advisor
34.34%
Investment Advisor/Hedge Fund
25.10%
Research Firm
3.90%
Pension Fund
1.27%
Sovereign Wealth Fund
0.91%
Individual Investor
0.56%
Bank and Trust
0.34%
Venture Capital
0.06%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
670
173.25M
102.40%
-15.51M
2025Q2
671
174.83M
104.44%
-12.86M
2025Q1
688
177.74M
106.20%
-7.86M
2024Q4
643
167.35M
100.34%
-11.57M
2024Q3
599
161.17M
97.17%
-22.69M
2024Q2
603
166.04M
100.49%
-20.26M
2024Q1
612
167.37M
101.58%
-15.73M
2023Q4
589
164.89M
100.43%
-16.10M
2023Q3
560
161.37M
98.56%
-19.17M
2023Q2
557
164.35M
101.06%
-15.99M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Baker Bros. Advisors LP
42.90M
25.43%
+18.77K
+0.04%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
18.22M
10.8%
-552.34K
-2.94%
Jun 30, 2025
The Vanguard Group, Inc.
15.24M
9.03%
+61.01K
+0.40%
Jun 30, 2025
RTW Investments L.P.
9.00M
5.33%
+455.43K
+5.33%
Jun 30, 2025
State Street Investment Management (US)
6.18M
3.66%
-815.47K
-11.66%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.19M
1.89%
-1.07M
-25.06%
Jun 30, 2025
Point72 Asset Management, L.P.
3.17M
1.88%
-1.48M
-31.74%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.02M
1.79%
+69.58K
+2.36%
Jun 30, 2025
Citadel Advisors LLC
3.01M
1.79%
+2.72M
+922.43%
Jun 30, 2025
Palo Alto Investors LP
2.56M
1.52%
-100.72K
-3.78%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
Alger Weatherbie Enduring Growth ETF
3.79%
iShares Neuroscience and Healthcare ETF
3.51%
First Trust NYSE Arca Biotechnology Index Fund
3.16%
Invesco Biotechnology & Genome ETF
2.22%
ALPS Medical Breakthroughs ETF
2.12%
Invesco S&P SmallCap Health Care ETF
1.69%
Virtus LifeSci Biotech Products ETF
1.63%
Invesco S&P SmallCap 600 GARP ETF
1.14%
SPDR S&P Biotech ETF
1.07%
Invesco S&P SmallCap Quality ETF
0.67%
Ver más
Alger Weatherbie Enduring Growth ETF
Proporción3.79%
iShares Neuroscience and Healthcare ETF
Proporción3.51%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.16%
Invesco Biotechnology & Genome ETF
Proporción2.22%
ALPS Medical Breakthroughs ETF
Proporción2.12%
Invesco S&P SmallCap Health Care ETF
Proporción1.69%
Virtus LifeSci Biotech Products ETF
Proporción1.63%
Invesco S&P SmallCap 600 GARP ETF
Proporción1.14%
SPDR S&P Biotech ETF
Proporción1.07%
Invesco S&P SmallCap Quality ETF
Proporción0.67%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
